

LEGISLATIVE FISCAL OFFICE
Fiscal Note



Fiscal Note On: **SB 48** SLS 24RS 178

Bill Text Version: **ENGROSSED**

Opp. Chamb. Action:

Proposed Amd.:

Sub. Bill For.:

Date: April 7, 2024	1:46 PM	Author: TALBOT
Dept./Agy.: Insurance and Office of Group Benefits		Analyst: Patrice Thomas
Subject: Consensus Statements for Biomarker Testing, Penalties		

GENETICS EG NO IMPACT See Note Page 1 of 1
Provides for health insurance coverage of genetic testing for diseases and other medical conditions. (gov sig)

Present law requires health plans to cover biomarker testing for diagnosis, treatment, appropriate management, or ongoing monitoring. Present law provides a list of items demonstrated by medical and scientific evidence that biomarker testing provides clinical utility. Proposed law repeals the requirement of a specific appropriation before present law becomes effective and provides an effective date of January 1, 2025 for all health plans issued.

EXPENDITURES	2024-25	2025-26	2026-27	2027-28	2028-29	5 -YEAR TOTAL
State Gen. Fd.	\$0	\$0	\$0	\$0	\$0	\$0
Agy. Self-Gen.	\$0	\$0	\$0	\$0	\$0	\$0
Ded./Other	\$0	\$0	\$0	\$0	\$0	\$0
Federal Funds	\$0	\$0	\$0	\$0	\$0	\$0
Local Funds	\$0	\$0	\$0	\$0	\$0	\$0
Annual Total	\$0	\$0	\$0	\$0	\$0	\$0

REVENUES	2024-25	2025-26	2026-27	2027-28	2028-29	5 -YEAR TOTAL
State Gen. Fd.	\$0	\$0	\$0	\$0	\$0	\$0
Agy. Self-Gen.	\$0	\$0	\$0	\$0	\$0	\$0
Ded./Other	\$0	\$0	\$0	\$0	\$0	\$0
Federal Funds	\$0	\$0	\$0	\$0	\$0	\$0
Local Funds	\$0	\$0	\$0	\$0	\$0	\$0
Annual Total	\$0	\$0	\$0	\$0	\$0	\$0

EXPENDITURE EXPLANATION

There is no anticipated direct material effect on governmental expenditures as a result of this measure. Proposed law repeals the provision of specific appropriation and provides for an effective date of January 1, 2025, for all new health plans issued on or before the date. The Office of Group Benefits (OGB) reports no impact. The health actuary for the LA Department of Insurance (LDI) estimates that there will be no material cost impact on the private insurance industry as a result of this measure.

REVENUE EXPLANATION

There is no anticipated direct material effect on governmental revenues as a result of this measure.

Senate Dual Referral Rules
 13.5.1 >= \$100,000 Annual Fiscal Cost {S & H}
 13.5.2 >= \$500,000 Annual Tax or Fee Change {S & H}

House
 6.8(F)(1) >= \$100,000 SGF Fiscal Cost {H & S}
 6.8(G) >= \$500,000 Tax or Fee Increase or a Net Fee Decrease {S}

Alan M. Boxberger
Alan M. Boxberger
Legislative Fiscal Officer